CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 321 enrolled
Drug / intervention
GORE® VIABAHN® Endoprosthesisdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04706273
NCT04706273N/ACompleted
CompareCT.gov

GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study (JPS 16-03)

W.L.Gore & Associates·observational·Posted Jan 12, 2021·Updated Sep 20, 2024

In Brief

An observational study evaluating GORE® VIABAHN® Endoprosthesis for Peripheral Arterial Disease. Completed, enrolled 321 participants across 1 site.

Detailed Summary

This study will confirm device efficacy and safety in the clinical setting after the launch of the GORE® VIABAHN® Endoprosthesis for the treatment of symptomatic peripheral arterial disease in the superficial femoral arteries.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 12, 2021
Enrollment StartAug 25, 2016
Primary CompletionJul 11, 2019
Study CompletionDec 14, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.5 years ago

Interventions

GORE® VIABAHN® Endoprosthesisdevice

Participants receiving the GORE® VIABAHN® Endoprosthesis